Open AccessRACO‐1 modulates Hippo signalling in oesophageal squamous cell carcinoma
Author(s) -
Pang Dan,
Wang Weilong,
Zhou Xiaofeng,
Lu Kui,
Zhang Jinghang,
Chen Zhiguo,
Wang Lingchao,
Shen Fangfang,
Chen Zhen,
Wang Sujie,
Hou Jinghan,
Zhang Aijia,
Lv Benjie,
Gao Can,
Yan Ziyi,
Hu Yuhan,
Chang Tingmin,
Wang Lidong,
Li Xiumin
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15811
Subject(s) - hippo signaling pathway , cancer research , gene silencing , biology , ubiquitin , microbiology and biotechnology , cell , cancer , cell growth , regulator , signal transduction , gene , genetics
Oesophageal cancer is one of the most lethal malignancies worldwide, whereas the 5‐year survival is less than 20%. Although the detailed carcinogenic mechanisms are not totally clear, recent genomic sequencing data showed dysregulation of Hippo signalling could be a critical factor for oesophageal squamous cell carcinoma (ESCC) progression. Therefore, understanding of the molecular mechanisms that control Hippo signalling activity is of great importance to improve ESCC diagnostics and therapeutics. Our current study revealed RACO‐1 as an inhibitory protein for YAP/TEAD axis. Depletion of RACO‐1 increases the protein level of YAP and expression of YAP/TEAD target gene. Besides, RACO‐1 silencing could promote ESCC cell invasion and migration, which effect could be rescued by YAP depletion in ESCC cells. Immunoprecipitation showed that RACO‐1 associated with YAP and promote ubiquitination and degradation of YAP at k48 poly‐ubiquitination site. Our research discovered a new regulator of Hippo signalling via modulating YAP stability. RACO‐1 could be a promising factor, which serves cancer diagnostics and therapeutics in ESCC patients.